These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32366281)

  • 1. The impact of sex and gender on immunotherapy outcomes.
    Klein SL; Morgan R
    Biol Sex Differ; 2020 May; 11(1):24. PubMed ID: 32366281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
    Bucktrout SL; Bluestone JA; Ramsdell F
    Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review.
    Tadount F; Doyon-Plourde P; Rafferty E; MacDonald S; Sadarangani M; Quach C
    Vaccine; 2020 Jan; 38(3):444-459. PubMed ID: 31711676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.
    Stapleton JT; Wagner N; Tuetken R; Bellamy AR; Hill H; Kim S; Winokur PL
    Vaccine; 2020 May; 38(23):3934-3941. PubMed ID: 32295718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?].
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Banna GL
    Recenti Prog Med; 2018 Nov; 109(11):540-546. PubMed ID: 30565573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.
    Alvarez M; Otano I; Minute L; Ochoa MC; Perez-Ruiz E; Melero I; Berraondo P
    Cell Stress; 2019 Jun; 3(7):236-239. PubMed ID: 31309173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapies - Overview, mode of action and clinical implications].
    Bill R; Schardt J
    Ther Umsch; 2019 Sep; 76(4):187-194. PubMed ID: 31498037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course.
    Flanagan KL; Fink AL; Plebanski M; Klein SL
    Annu Rev Cell Dev Biol; 2017 Oct; 33():577-599. PubMed ID: 28992436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in prophylaxis and therapeutic treatments for viral diseases.
    Klein SL
    Handb Exp Pharmacol; 2012; (214):499-522. PubMed ID: 23027464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.